[go: up one dir, main page]

WO2003013605A1 - Remedies for prostatic diseases - Google Patents

Remedies for prostatic diseases Download PDF

Info

Publication number
WO2003013605A1
WO2003013605A1 PCT/JP2002/008016 JP0208016W WO03013605A1 WO 2003013605 A1 WO2003013605 A1 WO 2003013605A1 JP 0208016 W JP0208016 W JP 0208016W WO 03013605 A1 WO03013605 A1 WO 03013605A1
Authority
WO
WIPO (PCT)
Prior art keywords
prostatic
interactions
lpa
cells
epithelial cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/008016
Other languages
French (fr)
Japanese (ja)
Inventor
Masahiro Furuno
Takayuki Naito
Yoshihisa Yamamoto
Junken Aoki
Hiroyuki Arai
Yoshiyuki Kakehi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of WO2003013605A1 publication Critical patent/WO2003013605A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

It is intended to prevent and treat prostatic diseases. More specifically speaking, it is found out that the causes and mechanisms of the onset of prostatic diseases closely relate to interactions among LPA receptors expressed in epithelial cells and LPA serving as a ligand thereof and the interactions among various physiologically active substances thus secreted from the prostatic epithelial cells and prostatic interstitial cells; that prostatic interstitial cells proliferate owing to these interactions; and that a substance inhibiting the interactions between the LPA receptors and LPA inhibits the proliferation of prostatic cells. Based on these findings, there are provided medicinal compositions containing, as the active ingredient, a substance inhibiting intracellular signal transduction induced by stimulus mediated by Edg-7 receptor which is one of the LPA receptors and frequently expressed in prostatic epithelial cells. Using these compositions, the signal transduction and secretion of the physiologically active substances as described above are inhibited. It is intended that prostatic diseases can be thus prevented and/or treated.
PCT/JP2002/008016 2001-08-07 2002-08-06 Remedies for prostatic diseases Ceased WO2003013605A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-239306 2001-08-07
JP2001239306 2001-08-07
JP2002-224215 2002-07-31
JP2002224215 2002-07-31

Publications (1)

Publication Number Publication Date
WO2003013605A1 true WO2003013605A1 (en) 2003-02-20

Family

ID=26620108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008016 Ceased WO2003013605A1 (en) 2001-08-07 2002-08-06 Remedies for prostatic diseases

Country Status (1)

Country Link
WO (1) WO2003013605A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517996B2 (en) 2003-08-05 2009-04-14 Ajinomoto Co., Inc. Azole compound

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518769A1 (en) * 1991-06-14 1992-12-16 Adir Et Compagnie Ethanolaminebenzoate derivative, process for their preparation and pharmaceutical compositions containing them
EP0878479A2 (en) * 1997-05-13 1998-11-18 Smithkline Beecham Corporation G-protein coupled receptor (HOFNH30)
WO1999067383A1 (en) * 1998-06-22 1999-12-29 Japan Tobacco Inc. Novel g protein-coupled receptor protein, dna and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0518769A1 (en) * 1991-06-14 1992-12-16 Adir Et Compagnie Ethanolaminebenzoate derivative, process for their preparation and pharmaceutical compositions containing them
EP0878479A2 (en) * 1997-05-13 1998-11-18 Smithkline Beecham Corporation G-protein coupled receptor (HOFNH30)
WO1999067383A1 (en) * 1998-06-22 1999-12-29 Japan Tobacco Inc. Novel g protein-coupled receptor protein, dna and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BANDOH K., AOKI J. ET AL.: "Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid", J. BIOL. CHEM., vol. 274, no. 39, 1999, pages 27776 - 27785, XP000990175 *
FITZGERALD L.R. ET AL.: "Identification of an EDG7 variant, HOFNH30, a G-protein-coupled receptor for lysophosphatidic acid", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 273, no. 3, 2000, pages 805 - 810, XP002957397 *
IM D.S. ET AL.: "Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate", MOL. PHARMACOL., vol. 57, no. 4, 2000, pages 753 - 759, XP002957398 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517996B2 (en) 2003-08-05 2009-04-14 Ajinomoto Co., Inc. Azole compound

Similar Documents

Publication Publication Date Title
WO2005107726A3 (en) Method for the treatment of back pain
MXPA05013824A (en) 5-membered heterocycle-based p38 kinase inhibitors.
IL172082A0 (en) Foamable pharmaceutical compositions and methods for treating a disorder
WO2008045228A3 (en) Medical devices having porous regions for controlled therapeutic agent exposure or delivery
PL1635824T3 (en) 5-membered heterocycle-based p-38 inhibitors
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
WO2005041925A3 (en) Compositions and dosage forms for enhanced absorption
EP2116245A3 (en) EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
JO2373B1 (en) W-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinease Inhibitors
MXPA02010618A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta.
MXPA03007857A (en) Compounds and compositions for delivering active agents.
ATE311373T1 (en) OXADIAZOLE COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE INGREDIENTS
MY144897A (en) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
WO2007049098A3 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
WO2005034883A3 (en) A method of healing skin wounds in mammals and a composition therefor
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
WO2005016306A3 (en) Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
WO2004034975A3 (en) Sustained release profile modification
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
TW200509998A (en) Controlled release of highly soluble agents
WO2005020957A3 (en) Stepwise delivery of topiramate over prolonged period of time
WO2005004854A3 (en) Use of betaine for treating arteritis
MXPA02003484A (en) Synergistic combinations of an nk1.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP